Veracyte secures Medicare coverage: 11 analysts rate Veracyte stock

Published on 10/18/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Prosigna gained Medicare coverage on October 16, 2026. For Veracyte stock, second-quarter revenue reached USD 150.32 million, up 15.5 percent year over year.

Coverage and financial milestones

Medicare coverage for Prosigna became effective on August 19, 2026.
Second-quarter revenue reached USD 150.32 million, up 15.5 percent year over year.
Veracyte will release third-quarter 2026 results on November 4, 2026.

VCYT, US92337F1075, Illustration mit AI erstellt.

Veracyte (US92337F1075) secured Medicare coverage for its Prosigna Breast Risk of Recurrence test on October 16, 2026. In a release dated October 16, 2026, Veracyte said the decision created a reimbursement path for eligible patients with early-stage breast cancer. MarketBeat reported on October 11, 2026, that 11 analysts held a Moderate Buy consensus on Veracyte stock, with an average USD 55.78 target.

Coverage reaches defined patients

The coverage became effective on August 19, 2026, and applies to postmenopausal women with stage I or II estrogen receptor positive breast cancer and 0-3 positive lymph nodes. The reimbursement decision followed Prosigna's U.S. launch in June 2026, giving the test a clearer route into Medicare-supported care.

Three milestones shape the story

Veracyte's recent chronology includes the acquisition of Convergent Genomics on September 14, 2026, phase III Decipher findings presented on September 29, 2026, and the Prosigna reimbursement decision on October 16, 2026. The first two dates appear on Veracyte's investor-relations page, while the reimbursement decision covered patients with stage I or II disease and 0-3 positive lymph nodes.

What does coverage mean for growth?

Veracyte generated USD 150.32 million in revenue in the second quarter of 2026, up 15.5 percent from the same period a year earlier. MarketBeat reported that diluted earnings per share reached USD 0.54 against a USD 0.41 consensus estimate for that quarter. The reimbursement milestone therefore adds a coverage event to a business that already delivered double-digit year-over-year revenue growth.

Next reporting date

Veracyte will release third-quarter 2026 financial results after the market close on November 4, 2026, followed by a conference call at 4:30 p.m. ET. The date and schedule were announced by Veracyte on October 14, 2026.

Nasdaq valuation remains measurable

The Nasdaq close was USD 43.12 on October 16, 2026, against a 52-week range of USD 29.45 to USD 60.91. Veracyte's market capitalization stood at USD 3.5 billion on that date. The further course of trading is shown by the continuously updated real-time quote of Veracyte stock.